John Galgiani, M.D. and Chaim Putterman, M.D. Join as Scientific Advisors to Enable Immunosignature Technology Application in Infectious and Autoimmune Diseases
HealthTell™, a Life Sciences company, announces John Galgiani, M.D., and Chaim Putterman, M.D., as Clinical Advisors.
“HealthTell is excited to welcome Dr. Galgiani and Dr. Putterman to our growing team of Clinical Advisors. They will provide valuable insights to expand our focus beyond oncology to infectious and autoimmune diseases,” said Bill Colston, Ph.D., CEO of HealthTell. “Our robust and unique test provides a snapshot of the immune system’s response to disease. We are grateful to have the opportunity to collaborate with clinicians and researchers of this caliber.”
Valley Fever is an infectious disease caused by fungus from the soil that is released into the air. It is endemic to Arizona and the San Joaquin Valley of California. While not a very prevalent disease, it results in over 20,000 infections annually. Often it is confused with community-acquired pneumonia and treated erroneously with antibiotics. In a small percent of patients it can be life threatening. Dr. Galgiani has devoted his career to raising awareness and improving outcomes for people affected by Valley Fever. He is the Director of the Valley Fever Center for Excellence and a tenured professor at the University of Arizona College of Medicine with 35 years of experience in medical mycology.
Dr. Chaim Putterman is Chief of the Division of Rheumatology and Professor of Medicine, Microbiology and Immunology at the Albert Einstein College of Medicine in New York. The principal investigator on several research projects funded by the National Institutes of Health (NIH) involving systemic lupus erythematosus (SLE), Dr. Putterman provides expertise for this debilitating and complicated disease in which the immune system produces antibodies to cells within the body, leading to extensive inflammation and tissue damage. The Lupus Foundation of America estimates that 1.5 million Americans suffer from SLE (often referred to as lupus), a disease which primarily affects women. New diagnostics are necessary to provide earlier detection of lupus, better monitor patients and help prevent progression of the disease.
HealthTell is an early stage Life Sciences company that utilizes an Immunosignature™ Technology for accurate and timely detection and monitoring of more than 30 progressive diseases. Based on robust, proprietary technology, the company is developing the first and only diagnostic platform capable of assessing an individual’s immune system response to specific diseases. This disruptive technology enables physicians to detect the presence or absence of a disease in its earliest stage, improving patient outcomes and reducing healthcare expenditures. Applicable to a broad range of therapeutic areas, HealthTell is empowering physicians and patients to proactively manage one’s health and make more informed decisions. For more information, please visit: http://www.healthtell.com/